voyagertherapeutics.com (VYGR) - Long-Term Liabilities to Capital

Voyager Therapeutics (VYGR) is recognized as a leading developer of CNS drug delivery systems, as evidenced by major contracts with industry leaders. This chart from GURU.Markets illustrates the price action of the asset, which currently stands at 0.18. The business relies on its unique TRACER technology to cross the blood-brain barrier for dementia therapy. Additionally, the company is integrating AI into molecular design, combining plant automation with deep scientific expertise.

For Voyager Therapeutics (VYGR), whose gene therapy costs are offset by advances from pharma behemoths, this indicator determines the balance between borrowed funds and equity. By analyzing the long-term capital structure ratio, an investor assesses the ratio of liabilities with a maturity of over one year to equity, which helps identify default risks or inefficient resource freezing, thereby confirming the issuer's overall financial stability.